Company (Location) Product Description Indication Status Date AUTOIMMUNE Creabilis SA (Luxembourg) CT327 Topical TrkA kinase inhibitor Chronic pruritis caused by psoriasis Phase IIb data showed a statistically significant and clinically meaningful reduction in pruritus of 60 percent compared to 20 percent for those receiving placebo 5/13/13 Idera Pharmaceuticals Inc. (Cambridge, Mass.) IMO-3100 A selective antagonist of Toll-like receptors 7 and 9 Psoriasis Phase II data showed improvements
upon successful completion of the Phase III, AbbVie will pay Galapagos $50M 5/20/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found
Total Value in 2013: $7,174M* Number of Deals in 2013: 119 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Advaxis Inc. (Princeton, N.J.) FusionVax Inc. (Taiwan) ND Memorandum of understanding under which Advaxis will, subject to a definitive agreement, exclusively license ADXS-HPV to FusionVax for development in Asia Advaxis will license rights for the Asia territory, exclusive of India, for all indications; FusionVax will make an up-front payment
ND Agreement to produce and supply 123I-labeled NAV5001 for Navidea's late-phase clinical trials The deal focuses on Nordion's cGMP manufacturing and supply of NAV5001 clinical trial material to be produced at Nordion's facility in Vancouver, British Columbia 5/17/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found
the deal was part of a $498M orphan disease deal in 2010 5/3/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International
Oxford expects to receive between £2.5M and £4M from Novartis over the next 12 months 5/2/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International
Total Value in 2013: $6,192M* Number of Deals in 2013: 97 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Alchemia Ltd. (Brisbane, Australia) AstraZeneca AB (Sodertalje, Sweden; unit of AstraZeneca plc) $240 Deal for Alchemia's Diversity Scanning Array and Versatile Assembly on Stable Templates technologies to discover and develop small molecules for multiple targets in the oncology, respiratory, cardiovascular, metabolism, infection and neuroscience
Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement
news item can be found